Adherence to antiretroviral therapy: Factors independently associated with reported difficulty taking antiretroviral therapy in a national sample of HIV-positive Australians

HIV Medicine

Volumn 12, Issue 9, 2011, Pages 562-569

  Grierson, J ^a   Koelmeyer, R L ^a   Smith, A ^a   Pitts, M ^a  

^a LA TROBE UNIVERSITY   (Australia)

Author keywords

Adherence; Antiretroviral therapy; Australia; HIV; Nonadherence

Indexed keywords

ANTIRETROVIRUS AGENT;

ALCOHOL CONSUMPTION; ARTICLE; ATTITUDE TO HEALTH; AUSTRALIA; DRUG USE; HEALTH SERVICE; HEALTH SURVEY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MENTAL HEALTH; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK FACTOR; SELF REPORT; SOCIOECONOMICS;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; AUSTRALIA; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; ODDS RATIO; QUESTIONNAIRES; SOCIOECONOMIC FACTORS; SUBSTANCE-RELATED DISORDERS; VIRAL LOAD; YOUNG ADULT;

EID: 79961162943     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2011.00928.x     Document Type: Article

References (34)

1. Mocroft A, Vella S, Benfield TL et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998; 352: 1725-1730.
2. Palella FJ, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-860.
3. Hoy J, Lewin S, Post JJ, Street A. (eds). HIV Management in Australasia: A Guide for Clinical Care. Darlinghurst, NSW: Australasian Society for HIV Medicine, 2009.
4. Paterson DL, Swindells S, Mohr J et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133: 21-30.
5. Bangsberg DR, Perry S, Charlebois E et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001; 15: 1181-1183.
6. Hogg R, Heath K, Bangsberg D et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS 2002; 16: 1051-1058.
7. Bangsberg D. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 2006; 43: 939-941.
8. Raffa JD, Tossonian HK, Grebely J, Petkau AJ, DeVlaming S, Conway B. Intermediate highly active antiretroviral therapy adherence thresholds and empirical models for the development of drug resistance mutations. J Acquir Immune Defic Syndr 2008; 47: 397-399.
9. Ammassari A, Trotta MP, Murri R et al. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr 2002; 31 (Suppl 3): S123-S127.
10. Spire B, Duran S, Souville M, Leport C, Raffi F, Moatti JP. Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach. Soc Sci Med 2002; 54: 1481-1496.
11. Falagas ME, Zarkadoulia EA, Pliatsika PA, Panos G. Socioeconomic status (SES) as a determinant of adherence to treatment in HIV infected patients: a systematic review of the literature. Retrovirology 2008; 5: 13.
12. Ammassari A, Antinori A, Cozzi-Lepri A et al. Relationship between HAART adherence and adipose tissue alterations. J Acquir Immune Defic Syndr 2002; 31 (Suppl 3): S140-S144.
13. Ammassari A, Murri R, Pezzotti P et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr 2001; 28: 445-449.
14. Atkinson MJ, Petrozzino JJ. An evidence-based review of treatment-related determinants of patients' nonadherence to HIV medications. AIDS Patient Care STDS 2009; 23: 903-914.
15. Eldred LJ, Wu AW, Chaisson RE, Moore RD. Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18: 117-125.
16. Sherr L, Lampe F, Norwood S et al. Adherence to antiretroviral treatment in patients with HIV in the UK: a study of complexity. AIDS Care 2008; 20: 442-448.
17. Kleeberger CA, Phair JP, Strathdee SA, Detels R, Kingsley L, Jacobson LP. Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 2001; 26: 82-92.
18. Aloisi MS, Arici C, Balzano R et al. Behavioral correlates of adherence to antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 31 (Suppl 3): S145-S148.
19. Braitstein P, Justice A, Bangsberg DR et al. Hepatitis C coinfection is independently associated with decreased adherence to antiretroviral therapy in a population-based HIV cohort. AIDS 2006; 20: 323-331.
20. Horne R, Buick D, Fisher M, Leake H, Cooper V, Weinman J. Doubts about necessity and concerns about adverse effects: identifying the types of beliefs that are associated with non-adherence to HAART. Int J STD AIDS 2004; 15: 38-44.
21. Bangsberg DR, Hecht FM, Charlebois ED et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000; 14: 357-366.
22. Lu M, Safren SA, Skolnik PR et al. Optimal recall period and response task for self-reported HIV medication adherence. AIDS Behav 2008; 12: 86-94.
23. Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, Frick PA. Self-report measures of antiretroviral therapy adherence: a review with recommendations for HIV research and clinical management. AIDS Behav 2006; 10: 227-245.
24. Mills EJ, Nachega JB, Bangsberg DR et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med 2006; 3: e438.
25. Grierson JG, Power J, Pitts M et al. HIV Futures 6: Making Positive Lives Count. Melbourne, Australia: The Australian Research Centre in Sex, Health and Society, Latrobe University, 2009.
26. Grierson J, Thorpe R, Pitts M. HIV Futures 5: Life As We Know It. Melbourne, Australia: The Australian Research Centre in Sex, Health and Society, Latrobe University, 2006.
27. Grierson J, Thorpe R, Saunders M, Pitts M. HIV Futures 4: State of the [Positive] Nation. Melbourne, Australia: The Australian Research Centre in Sex, Health and Society, Latrobe University, 2004.
28. Grierson J, Misson S, McDonald K, Pitts M, O'Brien M. HIV Futures 3: Positive Australians on Services, Health and Well-Being. Melbourne, Australia: The Australian Research Centre in Sex, Health and Society, Latrobe University, 2002.
29. Grierson J, Bartos M, de Visser R, McDonald K. HIV Futures II: The Health and Well-Being of People with HIV/AIDS in Australia. Melbourne, Australia: The Australian Research Centre in Sex, Health and Society, Latrobe University, 2000.
30. Ezzy D, De Visser R, Bartos M, McDonald K, O'Donnell D, Rosenthal D. HIV Futures Community Report: Health, Relationships, Community, and Employment. Carlton, Victoria, Australia: Centre for the Study of Sexually Transmissible Diseases, La Trobe University, 1998.
31. Rawstorne P, Prestage G, Grierson JG, Song A, Grulich A, Kippax S. Trends and predictors of HIV-positive community attachment among PLWHA. AIDS Care. 2005; 17: 589-600.
32. Commonwealth of Australia. National HIV/AIDS Strategy: Revitalising Australia's Response 2005-2008. Canberra: Commonwealth of Australia, 2005.
33. Fairley CK, Permana A, Read TRH. Long-term utility of measuring adherence by self-report compared with pharmacy record in a routine clinic setting. HIV Med 2005; 6: 366-369.
34. National Centre in HIV Epidemiology and Clinical Research. HIV/AIDS, Viral Hepatitis and Sexually Transmissible Infections in Australia Annual Surveillance Report 2009. Sydney, NSW: National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, 2009.